T-lymphoblastic lymphoma
diseaseOn this page
Also known as Precur. T-lymphoblastic lymphomaprecursor T Lymphoblastic lymphomaprecursor T-cell Lymphoblastic lymphomaprecursor T-Lymphoblastic lymphomaT Lymphoblastic lymphoma
Summary
T-lymphoblastic lymphoma (MONDO:0044917) is a cancer and 27 clinical trials. Top therapeutic interventions include mercaptopurine anhydrous, nelarabine, and pegaspargase. A subtype of lymphoblastic lymphoma — broader associated-gene and molecular evidence is on the parent page (see Disease family below).
At a glance
- Classification: Cancer
- Clinical trials: 27
Clinical features
No curated clinical features (Orphanet) for this disease.
Identifiers
Disease identifiers
| Field | Value |
|---|---|
| Canonical name | T-lymphoblastic lymphoma |
| Mondo ID | MONDO:0044917 |
| NCIT | C6919 |
| SNOMED CT | 421246008 |
| UMLS | C1292758 |
| MedGen | 266232 |
| GARD | 0025922 |
| Is cancer (heuristic) | yes |
Also known as: Precur. T-lymphoblastic lymphoma · precursor T Lymphoblastic lymphoma · precursor T-cell Lymphoblastic lymphoma · precursor T-Lymphoblastic lymphoma · precursor T-lymphoblastic lymphoma · T Lymphoblastic lymphoma · T-Lymphoblastic lymphoma · T-lymphoblastic lymphoma
Disease family
This is a subtype of lymphoblastic lymphoma. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.
Classification path: human disease › disease by etiologic mechanism › cancer or benign tumor › neoplastic disease or syndrome › neoplasm › hematopoietic and lymphoid system neoplasm › hematopoietic and lymphoid cell neoplasm › lymphoid neoplasm › precursor lymphoblastic lymphoma/leukemia › lymphoblastic lymphoma › T-lymphoblastic lymphoma
Related subtypes (1): T-cell childhood lymphoblastic lymphoma
Genetics & variants
GWAS landscape
No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.
Variant details and genetic-evidence tiers
No tiered GWAS variants or ClinVar records for this disease.
Genes & proteins
No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).
Function
No pathway enrichment — requires an associated-gene cohort.
Therapeutics
No druggable-target or therapeutic data for this disease’s cohort.
Clinical trials & evidence
Clinical trials
Clinical trials: 27.
Phase distribution (across all retrieved trials)
| Phase | Trials |
|---|---|
| PHASE2 | 7 |
| PHASE1 | 5 |
| PHASE1/PHASE2 | 4 |
| Not specified | 4 |
| EARLY_PHASE1 | 3 |
| PHASE3 | 2 |
| PHASE4 | 1 |
| PHASE2/PHASE3 | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT03558412 | PHASE4 | UNKNOWN | A Clinical Trial of Decitabine in Relapsed or Refractory T-lymphoblastic Lymphoma |
| NCT06434467 | PHASE3 | NOT_YET_RECRUITING | The Efficacy and Safety of Nelarabine Injection in Patients With T-lymphoblastic Leukemia and T-lymphoblastic Lymphoma |
| NCT07072585 | PHASE2/PHASE3 | NOT_YET_RECRUITING | Testing the Addition of Daratumumab to Chemotherapy for Treating Patients With Newly-Diagnosed T-Cell Lymphoblastic Leukemia (T-ALL) and T-Cell Lymphoblastic Lymphoma (T-LL) |
| NCT00408005 | PHASE3 | COMPLETED | Combination Chemotherapy in Treating Young Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or T-cell Lymphoblastic Lymphoma |
| NCT00501826 | PHASE2 | RECRUITING | Combination Chemotherapy and Nelarabine in Treating Patients With T-cell Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma |
| NCT03504644 | PHASE1/PHASE2 | ACTIVE_NOT_RECRUITING | Venetoclax and Vincristine in Treating Patients With Relapsed or Refractory T-cell or B-cell Acute Lymphoblastic Leukemia |
| NCT04315324 | PHASE1/PHASE2 | RECRUITING | Study to Test OBI-3424 in Patients With T-Cell Acute Lymphoblastic Leukemia (T-ALL) or T-Cell Lymphoblastic Lymphoma (T-LBL) |
| NCT06376721 | PHASE1/PHASE2 | RECRUITING | Linperlisib Combined With Camrelizumab and Pegaspargase in Advanced or Relapsed/Refractory NK/T-cell Lymphoma |
| NCT07523555 | PHASE1/PHASE2 | RECRUITING | Adaptive Dual-Target CAR-T Cells for Relapsed or Refractory Hematologic Malignancies |
| NCT01028716 | PHASE2 | TERMINATED | Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies |
| NCT02538926 | PHASE2 | WITHDRAWN | Etoposide, Prednisone, Vincristine Sulfate, Cyclophosphamide, and Doxorubicin Hydrochloride With Asparaginase in Treating Patients With Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma |
| NCT02999633 | PHASE2 | TERMINATED | Safety and Efficacy of Isatuximab in Lymphoblastic Leukemia |
| NCT05576532 | PHASE2 | UNKNOWN | Venetoclax Plus IM2 Regimen for Relapsed and Refractory T Lymphoblastic Lymphoma/Leukemia |
| NCT05745181 | PHASE2 | UNKNOWN | Clinical Study of Anti-CD1a CAR-T in the Treatment of R/R Acute T-lymphoblastic Leukemia/Lymphoblastic Lymphoma |
| NCT06210750 | PHASE2 | WITHDRAWN | Adding Targeted Drugs to Usual Chemotherapy for Adults With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia (T-ALL) and T-Cell Lymphoblastic Lymphoma (T-LBL) |
| NCT06136364 | PHASE1 | RECRUITING | CD7 CAR-T in Adults With Relapsed or Refractory T-LBL/ALL Clinical Study |
| NCT01363817 | PHASE1 | COMPLETED | Study to Evaluate the Safety and Tolerability of Weekly Intravenous (IV) Doses of BMS-906024 in Subjects With Acute T-cell Lymphoblastic Leukemia or T-cell Lymphoblastic Lymphoma |
| NCT04004637 | PHASE1 | UNKNOWN | CD7 CAR-T Cells for Patients With R/R CD7+ NK/T Cell Lymphoma,T-lymphoblastic Lymphoma and Acute Lymphocytic Leukemia |
| NCT04828174 | PHASE1 | SUSPENDED | Anti-TRBC1 CAR-T Cell Therapy in Patients With TRBC1 Positive T Cell Malignancies |
| NCT05170828 | PHASE1 | WITHDRAWN | Cryopreserved MMUD BM With PTCy for Hematologic Malignancies |
| NCT06633341 | EARLY_PHASE1 | RECRUITING | Targeting CD5 CAR-T Cells in the Treatment of r/r CD5+ T-lymphoma |
| NCT07476027 | EARLY_PHASE1 | NOT_YET_RECRUITING | Efficacy and Safety of CD7 CAR-T in Newly Diagnosed High-Risk T-LBL/ALL |
| NCT04860817 | EARLY_PHASE1 | WITHDRAWN | A Study of Anti-CD7 CAR-T Cells in Pediatric and Young Adult Patients With Relapse and Refractory T-ALL/ T-LBL |
| NCT06741813 | Not specified | NOT_YET_RECRUITING | Allo-HSCT vs ASCT in Adult T-LBL |
| NCT04320992 | Not specified | UNKNOWN | A Multicenter Prospective Study of High Risk Molecular Typing in Patients With Adult T Lymphoblastic Lymphoma |
| NCT04582487 | Not specified | UNKNOWN | Advancing Chemical and Genomic Strategies for Relapsed/Refractory T-ALL and ETP-ALL |
| NCT04620655 | Not specified | UNKNOWN | RD13-01 for Patients With r/r CD7+ T-ALL/T-LBL |
Drugs tested across these trials (top 30)
| Molecule | Max phase | Trials referencing |
|---|---|---|
| MERCAPTOPURINE ANHYDROUS | 4 | 7 |
| NELARABINE | 4 | 5 |
| PEGASPARGASE | 4 | 3 |
| THIOGUANINE | 4 | 3 |
| ASPARAGINASE | 4 | 2 |
| CALASPARGASE PEGOL | 4 | 2 |
| 2-MERCAPTOETHANESULFONIC ACID | 4 | 1 |
| DARATUMUMAB | 4 | 1 |
| DAUNORUBICIN | 4 | 1 |
| DECITABINE | 4 | 1 |
| DIPHENHYDRAMINE | 4 | 1 |
| ISATUXIMAB | 4 | 1 |
| LEUCOVORIN | 4 | 1 |
| RANITIDINE | 4 | 1 |
| VENETOCLAX | 4 | 1 |
| NAVITOCLAX | 3 | 1 |
| LINPERLISIB | 2 | 1 |
| OSUGACESTAT | 2 | 1 |
| CHEMBL3970001 | 0 | 1 |
| ZEBULARINE | 0 | 1 |